Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

PeproMene Bio

Tracked across 2 events · 12 articles · First seen May 28, 2026 · Last active Sep 08, 2026

Sentiment
82
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 75
Tech
Impact: As the developer of PMB-CT01, PeproMene Bio is the central entity in this event, benefiting from positive clinical trial results that validate its therapeutic approach and potentially increase its market value and future commercialization prospects.
May 28, 2026 · 6 articles
4 90
Tech
PeproMene Bio announced the publication in The Lancet of results from its Phase 1 clinical trial of PMB-CT01, a first-in-class BAFF-R-targeted CAR T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The trial…
Impact: As the developer of PMB-CT01, PeproMene Bio is the primary beneficiary. The positive results and publication could significantly boost its prospects for funding, partnerships, and eventual commercialization.
Jul 20, 2026 · 6 articles
ERGEN INTELLIGENCE
Track PeproMene Bio live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.